Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real …
YS Punekar, D Parks, M Joshi, S Kaur, L Evitt… - HIV …, 2021 - Wiley Online Library
Objectives Dolutegravir (DTG) is widely recommended within three‐drug regimens.
However, similar efficacy and tolerability have also been achieved with DTG within two‐drug …
However, similar efficacy and tolerability have also been achieved with DTG within two‐drug …
Pharmacist-involved antiretroviral stewardship programs in people living with HIV/AIDS: a systematic review
People living with human immunodeficiency virus/acquired immunodeficiency syndrome
(HIV/AIDS; PLWHA) frequently encounter antiretroviral (ARV) therapy-related problems …
(HIV/AIDS; PLWHA) frequently encounter antiretroviral (ARV) therapy-related problems …
Integrase inhibitor resistance mechanisms and structural characteristics in antiretroviral therapy-experienced, integrase inhibitor-naive adults with HIV-1 infection …
M Underwood, J Horton, K Nangle… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI)
dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to …
dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to …
[HTML][HTML] Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: an open-label randomized controlled trial in …
A Amstutz, BL Nsakala, F Vanobberghen… - PLoS …, 2020 - journals.plos.org
Background Current World Health Organization (WHO) antiretroviral therapy (ART)
guidelines define virologic failure as two consecutive viral load (VL) measurements≥ 1,000 …
guidelines define virologic failure as two consecutive viral load (VL) measurements≥ 1,000 …
Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive review
The discovery of anti‐retroviral (ARV) drugs over the past 36 years has introduced various
classes, including nucleoside/nucleotide reverse transcriptase inhibitors, non‐nucleoside …
classes, including nucleoside/nucleotide reverse transcriptase inhibitors, non‐nucleoside …
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
T Clemente, L Galli, R Lolatto, R Gagliardini, F Lagi… - BMJ open, 2024 - bmjopen.bmj.com
Purpose The PRESTIGIO Registry was established in 2017 to collect clinical, virological and
immunological monitoring data from people living with HIV (PLWH) with documented four …
immunological monitoring data from people living with HIV (PLWH) with documented four …
The case of multiple HIV virological failures in a compliant patient: do pharmacogenetics matter?
D Cattaneo, N Astuti, C Montrasio… - Journal of …, 2024 - academic.oup.com
Virological failure is generally the result of a combination of factors including reduced
adherence, drug resistance mutations and/or suboptimal pharmacokinetic exposure. 1 The …
adherence, drug resistance mutations and/or suboptimal pharmacokinetic exposure. 1 The …
Characterization of heavily treatment-experienced people with HIV and impact on health care resource utilization in US commercial and Medicare Advantage health …
J Priest, E Hulbert, BL Gilliam… - Open Forum Infectious …, 2021 - academic.oup.com
Background This retrospective administrative claims study aimed to describe clinical
characteristics, health care resource utilization (HCRU), and costs of people with HIV (PWH) …
characteristics, health care resource utilization (HCRU), and costs of people with HIV (PWH) …
The evolution of clinical study design in heavily treatment-experienced persons with HIV: a critical review
JA Aberg, A Mills, S Moreno, J Slater… - Antiviral …, 2023 - journals.sagepub.com
Heavily treatment-experienced (HTE) persons with HIV have limited options for antiretroviral
therapy and face many challenges, complicating their disease management. There is an …
therapy and face many challenges, complicating their disease management. There is an …
[HTML][HTML] Indirect treatment comparisons of lenacapavir plus optimized background regimen versus other treatments for multidrug-resistant human immunodeficiency …
I Chatzidaki, T Curteis, H Luedke, DJ Mezzio, MS Rhee… - Value in Health, 2023 - Elsevier
Abstract Background/Aims Heavily treatment-experienced (HTE) people with human
immunodeficiency virus (HIV)(PWH) may not achieve virologic suppression (VS) with …
immunodeficiency virus (HIV)(PWH) may not achieve virologic suppression (VS) with …